Automated Drug Compounding Systems Market Outlook: Strong Revenue and CAGR Growth Forecast Through 2030

 What Are the Key Growth Indicators and Market Expansion Estimates for the Automated Drug Compounding Systems Market Through 2030?

 The automated drug compounding systems market size has grown rapidly in recent years. It will grow from $1.85 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increasing adoption of automated systems in hospital pharmacies, rising need to minimize medication errors, growing focus on sterile and accurate drug preparation, increasing workflow burden on pharmacy staff, and rising demand for time-saving compounding processes.

 
 The automated drug compounding systems market size is expected to see rapid growth in the next few years. It will grow to $3.28 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to growing investment in healthcare automation, increasing integration of software and automation tools, rising need for standardization in drug compounding, growing focus on reducing contamination risks, increasing hospital spending on automation infrastructure, and rising need for operational efficiency in pharmacies. Major trends in the forecast period include advancement in robotic-assisted drug compounding technologies, innovation in software integration for pharmacy management, integration of AI for error reduction in compounding processes, advancement in real-time monitoring and quality control systems, and innovation in automated sterile compounding techniques.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=30527&type=smp
 
 Which Primary Drivers Are Expected to Shape the Future of the Automated Drug Compounding Systems Market?
 The increasing prevalence of chronic diseases is expected to propel the growth of the automated drug compounding systems market going forward. Chronic diseases are long-lasting health conditions that usually progress slowly over time, such as diabetes, heart disease, and arthritis, and often require ongoing medical attention and lifestyle management to control symptoms and prevent complications. Chronic diseases are increasing largely due to unhealthy lifestyles, including poor diet, physical inactivity, and smoking, which raise the risk of conditions such as diabetes, heart disease, and obesity. Automated drug compounding systems aid in chronic disease management by precisely preparing individualized medications tailored to each patient’s needs. They improve treatment accuracy and consistency, reducing errors and enhancing long-term therapeutic outcomes. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing prevalence of chronic diseases is driving the growth of the automated drug compounding systems market.
 
 Shortage Of Skilled Pharmacy Staff Fueling The Growth Of The Market Due To Rising Demand For Automated Medication Preparation Solutions
 
 The shortage of skilled pharmacy staff is expected to propel the growth of the automated drug compounding systems market going forward. The shortage of skilled pharmacy staff refers to the limited availability of trained pharmacists and technicians capable of safely preparing and dispensing medications in hospitals, clinics, and compounding pharmacies. The rise in the shortage of skilled pharmacy staff is due to increasing patient loads and the growing prevalence of chronic diseases requiring precise pharmaceutical care. Automated drug compounding systems reduce reliance on skilled pharmacy staff by enabling accurate, consistent, and efficient preparation of medications with minimal human intervention, reducing errors and workload for pharmacy staff. For instance, in August 2024, according to the National Center for Health Workforce Studies, a US-based health workforce research organization, projections indicate a shortage of 4,980 pharmacists over the next 15 years through 2036, while overall demand for pharmacists is expected to grow 3% from 2022 to 2032, raising concerns amid declining application trends. Therefore, the shortage of skilled pharmacy staff is driving the growth of the automated drug compounding systems market.
 
 What Are the Primary Market Segments in the Automated Drug Compounding Systems Market?
 The automated drug compounding systems market covered in this report is segmented — 
 
 1) By Product: Robotic Compounding Systems, Automated Liquid Compounding Systems, Tablet And Capsule Dispensers, Injectable Compounding Robots, IV Admixture Systems, Oral Liquid Compounding Systems
 2) By Component: Equipment, Software, Consumables, Services
 3) By Technology: Robotic-Based Systems, Semi-Automated Systems, Gravimetric Dosing Systems, Volumetric Dosing Systems, Hybrid Dosing Systems
 4) By End-User: Hospitals, Clinics, Retail Pharmacies, Compounding Pharmacies, Pharmaceutical Manufacturers
 
 Subsegments:
 1) By Robotic Compounding Systems: Fully Automated Sterile Compounding Robots, Hazardous Drug Compounding Robots, Non-Hazardous Drug Compounding Robots, High-Throughput Pharmacy Robots, Closed-System Robotic Compounding Units
 2) By Automated Liquid Compounding Systems: Large-Volume Parenteral (LVP) Compounding Systems, Small-Volume Parenteral (SVP) Compounding Systems, Multi-Drug Liquid Compounding Units, Volumetric And Gravimetric Liquid Compounding Systems, Pediatric Liquid Dosing Compounding Systems
 3) By Tablet and Capsule Dispensers: Automated Tablet Counting Dispensers, Unit-Dose Packaging Systems, Multi-Dose Blister Dispensing Units, Capsule Filling and Dispensing Systems, High-Speed Pharmacy Dispensing Robots
 4) By Injectable Compounding Robots: Chemotherapy Drug Compounding Robots, TPN (Total Parenteral Nutrition) Compounding Robots, High-Precision Syringe Preparation Robots, Sterile Injectable Filling Robots, Hazardous Injectable Handling Systems
 5) By IV Admixture Systems: Automated IV Bag Filling Systems, IV Nutrition (TPN) Admixture Systems, IV Antibiotic Admixture Devices, Pharmacy Cleanroom IV Automation Units, Closed-System IV Compounding Systems
 6) By Oral Liquid Compounding Systems: Pediatric Oral Liquid Compounding Machines, Flavoring & Suspension Mixing Systems, Multi-Ingredient Oral Liquid Compounding Units, Gravimetric Oral Solution Compounding Systems, Low-Volume Oral Dosing Compounding Systems
 
 Which Disruptive Trends Are Reshaping the Competitive Landscape of the Automated Drug Compounding Systems Market?
 Major companies operating in the automated drug compounding systems market are focusing on developing advanced systems, such as total parenteral nutrition (TPN) automation systems, to improve accuracy, safety, and efficiency in preparing personalized intravenous formulations. A total parenteral nutrition (TPN) automation system refers to a compounding platform that not only automates the mixing and dispensing of total parenteral nutrition (TPN) solutions but also integrates prescription validation and workflow management tools to reduce human error and ensure sterile, high-quality preparation. For instance, in May 2025, MediServ Co. Ltd., launched the APEX TPN Compounding System in Riyadh, ushering in a new era of precision and automation for parenteral nutrition workflows. The system, showcased with its EasyComp integration software, enhances the total parenteral nutrition (TPN) process by linking validated prescriptions through to sterile, accurate compounding, streamlining pharmacy operations and reducing manual tasks.
 
 Who Are the Key Strategic Players in the Automated Drug Compounding Systems Market Ecosystem?
 Major companies operating in the automated drug compounding systems market are Becton Dickinson and Company, Baxter International Inc., B. Braun Melsungen AG, Fresenius Kabi AG, ICU Medical Inc., Omnicell Inc., Eckert & Ziegler SE, Swisslog Healthcare AG, EQUASHIELD Medical Ltd., Trasis S.A., Loccioni Group S.p.A., ARxIUM Inc., Comecer S.p.A., Tema Sinergie S.p.A., Epic Medical Pte. Ltd., IBA Radiopharma Solutions S.A., Steriline S.r.l., Elysia-Raytest GmbH, Curifylabs OY, Kapsam Health Solutions Pvt. Ltd. 
 
 Get the detailed automated drug compounding systems market report today
 https://www.thebusinessresearchcompany.com/report/automated-drug-compounding-systems-market-report
 
 What Are the Fastest-Growing Regions in the Automated Drug Compounding Systems Market?
 North America was the largest region in the automated drug compounding Systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the automated drug compounding systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 #Contact Us:#
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 #Follow Us On:#
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company